Navigation Links
Positive Glufosfamide Results From a Phase 2 Clinical Trial Presented at European Cancer Conference (ECCO)

REDWOOD CITY, Calif., Sept. 26 /PRNewswire-FirstCall/ -- Threshold Pharmaceuticals, Inc. (Nasdaq: THLD), today announced that results from a Phase 2 trial of glufosfamide plus gemcitabine were presented at the European Cancer Conference (ECCO) annual meeting in Barcelona, Spain.

In the Phase 2 clinical trial of glufosfamide in combination with gemcitabine for the treatment of advanced pancreatic cancer, six-month and one-year survival were 50% (95% CI: 31-67%) and 32% (95% CI: 16 - 49%), respectively. Median progression-free and overall survival were 3.7 and 6.0 months.

"We are encouraged by the results of this Phase 2 study, especially with respect to the one-year survival data which was higher than expected compared to previous studies of either gemcitabine alone or in combination with tarceva," said Barry Selick, Ph.D., chief executive officer of Threshold. "Based on these findings we believe that glufosfamide should have a role in the treatment of pancreatic cancer and, taken together with our Phase 3 results, we will be exploring the best options for its continued development in the treatment of this disease".

In a poster session at ECCO, Dr. Elena (Gabi) Chiorean, Indiana University Cancer Center, Indianapolis, IN, presented the Phase 2 results in a poster entitled, "Glufosfamide (GLU) plus gemcitabine (GEM) in pancreatic adenocarcinoma: results of a Phase 2 trial". In the clinical trial, 29 patients were treated, of which 28 patients with pancreatic adenocarcinoma previously untreated with chemotherapy were evaluated for response. Overall, 6 of 28 patients (21%; 95% CI: 8-41%) achieved a partial response including one unconfirmed partial response. Median duration of confirmed responses was 8.4 months. In addition, 11 of 28 patients (39%) experienced stable disease (duration 1.2+ to 12.6+ months). Objective response was assessed radiologically after every two cycles (8 weeks) of therapy. A partial response is characterized as a decrease in size by 30% of the sum of the longest diameters of target lesions, the absence of progression of all non-target lesions and no new lesions.

Grade 3 and 4 neutropenia occurred in 8 (28%) and 15 (52%) patients. Grade 3 and 4 thrombocytopenia occurred in 8 (28%) and 2 (7%) patients. Five patients (18%) had a glufosfamide-related serious adverse event (SAE), which included renal tubular acidosis (RTA) with renal failure (2 patients), RTA alone, vomiting or nausea. Three patients died from an SAE unrelated to glufosfamide. Another patient developed an SAE of renal failure after hypotension associated with pulmonary embolus. The creatinine clearance (CrCL) fell below 60 mL/min in 10 of 27 (37%) patients with CrCL greater than or equal to 60 at baseline.

These data indicate that glufosfamide plus gemcitabine may benefit patients with chemotherapy nave pancreatic adenocarcinoma. Hematologic and renal toxicity may be greater than would be expected with either agent alone although the small numbers preclude definitive conclusions. No unanticipated adverse events based on previous experience with glufosfamide were observed.

The Phase 2 poster is available on the Threshold website at

About Glufosfamide

Glufosfamide combines the active part of ifosfamide, a member of a widely used class of chemotherapy drugs known as "alkylators", with a glucose molecule. Because of its glucose component and a tumor cell's increased need for glucose, glufosfamide may be preferentially transported into tumors compared to most normal tissues. Inside cells, the linkage between glucose and the alkylator is cleaved to release the active drug.

About Pancreatic Cancer

The American Cancer Society estimates that 37,170 patients will be diagnosed with pancreatic cancer in the United States in 2007, and approximately 33,370 patients will die from the disease. Only 15-20% of newly diagnosed patients are eligible for surgery, which is typically followed by radiation and chemotherapy. Patients with inoperable pancreatic cancer are treated with radiation and chemotherapy, or in the case of metastatic disease, chemotherapy alone as the advantages of radiation are reduced.

About Threshold Pharmaceuticals

Threshold is a biotechnology company focused on the discovery and development of small molecule therapeutics for the potential treatment of cancer. By selectively targeting abnormally-proliferating tumor cells, the Company's drug candidates are designed to be potentially more effective and less toxic to healthy tissues than conventional treatments. For additional information, please visit our website (

Forward-Looking Statements

Except for statements of historical fact, the statements in this press release are forward-looking statements, including statements regarding Threshold's product candidates, clinical trial progress and results, potential therapeutic uses and benefits of our product candidates and financial projections. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, Threshold's ability to commence, enroll or complete its anticipated clinical trials, the time and expense required to conduct such clinical trials and analyze data, issues arising in the regulatory or manufacturing process and the results of such clinical trials (including product safety issues and efficacy results). The scientific information discussed in this news release related to our product candidate is preliminary and investigative. The product candidate is not approved by the U.S. Food and Drug Administration (FDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidate. Only the FDA can determine whether the product candidate is safe and effective for the use(s) being investigated. Further information regarding these and other risks is included under the heading "Risk Factors" in Threshold's Quarterly Report on Form 10-Q, which was filed with the Securities Exchange Commission on August 7, 2007 and is available from the SEC's website ( and on our website ( under the heading "Investors." We do not intend to update any forward-looking statement made in this news release.


Denise T. Powell

Sr. Director, Corporate Communications

Threshold Pharmaceuticals, Inc.


SOURCE Threshold Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
(Date:10/9/2015)... , Oct. 9, 2015  Impax Laboratories, Inc. ... will release its third quarter 2015 financial results on ... the U.S. financial markets. The Company will host a ... at 8:30 a.m., Eastern Time on November 9, 2015.  ... . --> The financial results and live ...
(Date:10/9/2015)... 9, 2015 Eli Lilly and Company (NYSE: ... and approximately 50 new jobs to its research and development ... New York, New York . ... space will include a translational immuno-oncology hub and a Lilly ... collaborative access to cutting-edge drug discovery capabilities, including chemistry and ...
(Date:10/9/2015)...   --> --> Phase ... San Diego, California , by Dr. Tom Lyon , ... Center, on 9 th October 2015 at 8:30a.m. PDT. ... Tom Lyon , Director of Orthopaedics and Chief of Orthopaedic Trauma, ... 8:30a.m. PDT. --> Kuros Biosurgery AG, a biotechnology company ...
Breaking Medicine Technology:
... Talecris Biotherapeutics (Nasdaq: TLCR ) today ... Administration for PROLASTIN®-C (Alpha1-Proteinase Inhibitor [Human]), a more ... manufacturing technology. , Like PROLASTIN, the market leader ... the treatment of alpha1-antitrypsin (AAT) deficiency, a genetic ...
... BRIDGEWATER, N.J., Oct. 16 Sanofi-aventis U.S. announced that ... marketing approval for Elitek® (rasburicase) to be used for ... in adult patients with leukemia, lymphoma, and solid tumor ... in tumor lysis syndrome (TLS) and subsequent elevations of ...
Cached Medicine Technology:
(Date:10/9/2015)... , ... October 09, 2015 , ... With the FCPX ... pop grades to footage. A LUT is a Lookup Table that contains a mathematical ... color indicated by the table. This pack comes with 60 vibrant CUBE LUT files. ...
(Date:10/9/2015)... ... October 09, 2015 , ... ... in The Tennessean's eighth annual Toast of Music City, a reader’s choice awards ... residents nominated and cast votes for their favorite businesses in over 200 categories, ...
(Date:10/9/2015)... ... ... On Saturday, September 26, 2015, 48-year-old MS survivor and entrepreneur Lucie B won ... USA and Sweden in the Speed and Power events, which consisted of 30-Second Single ... 1 Silver and 4 Gold Medals. , “I remember looking at my competitors and ...
(Date:10/9/2015)... ... 2015 , ... "As a nurse, I care for male patients who struggle ... wear large diapers or pads. We came up with this as a better alternative ... leaking from the tip of the penis. This prevents stains from forming on underwear ...
(Date:10/9/2015)... ... October 09, 2015 , ... Santa Rosa Consulting and The ... MD Anderson prepares to go-live on the Epic platform in March of 2016. Both ... Santa Rosa will execute the contract by supporting Scheduling Appointment Conversion and the Go-Live. ...
Breaking Medicine News(10 mins):
... eye of now co-editor Rick Drake and colleagues at the ... now the highest ranking journal in science education? If ... correct! As AAA publisher Wiley-Blackwell put it in a ... as the number 1 ranked journal in Education, Scientific Disciplines." ...
... scientists at Duke University Medical Center and Johns Hopkins ... of drug therapy to treat the second most common ... been looking for the primary cancer genes involved in ... that held the probable mutations, but not the particular ...
... Summer for most people means time spent outdoors, which ... arthropod-borne diseases, such as "rickettsial diseases" infectious diseases ... fleas, ticks and mites. Now a $1.6 million ... enable an entomologist at the University of California, Riverside ...
... Southwestern Medical Center researchers may suggest new strategies for successful ... such as leukemia, lymphoma and myeloma. The study, published ... the first time that adult blood stem cells can be ... rejection. It also opens up further studies in stem cell ...
... and are famous for their "work hard, play ... employees healthier too? According to a Tel Aviv University ... health benefits. Dr. Sharon Toker of the ... School of Business Administration says that employees who believe ...
... By Ellin Holohan HealthDay Reporter , THURSDAY, ... antidepressants than ever before to deal with everyday stress, ... to patients with no mental health diagnosis, a new ... Lexapro are now the third most widely prescribed group ...
Cached Medicine News:
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: